European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation

Predictive significance of the European LeukemiaNet classification of genetic aberrations in patients with acute myeloid leukaemia undergoing allogeneic stem cell transplantation

“…This negative impact of FLT3‐ITD is further underlined by multivariate analysis, showing that in the intermediate‐1 subgroup, FLT3‐ITD is an independent predictor for survival, both OS and DFS, and relapse incidence. In this regard, our data support the notion that the poor outcome of patients belonging to the ELN intermediate‐1 group is due to the high proportion harbouring a FLT3‐ITD . In the same vein, Ahn et al .…”

“…analysing a cohort of 364 patients with AML, 354 of which were aged ≤60 yr, transplanted in CR1 . Likewise, a smaller study of 106 patients published earlier came to a similar conclusion , whereas another report, which analysed data from four consecutive trials of the Dutch–Belgian Hemato‐Oncology Cooperative Group and the Swiss Group for Clinical Cancer Research group (HOVON‐SAKK) in a time‐dependent manner did not reveal major differences in outcome between the intermediate‐1 and intermediate‐2 risk group after alloSCT . However, patients in the latter study were aged 60 yr or above and overall outcome was inferior to what we found across all risk groups.…”

“…The current stratification of molecular genetic and cytogenetic aberrations according to the ELN recommendations has proved useful in predicting the overall outcome in larger cohorts of patients with AML undergoing intensive treatment . However, data on how the ELN classification predicts the outcome of patients with AML undergoing alloSCT are limited . Therefore, we assessed the predictive capacity of the ELN grouping scheme in a series of 274 patients with AML, who underwent first alloSCT at our centre between 2004 and 2014.…”

Successful treatment of post-transplant relapsed acute myeloid leukemia with FLT3 internal tandem duplication using the combination of induction chemotherapy, donor lymphocyte infusion, sorafenib and azacitidine. Report of three cases

“…(2) Although AML patients with FLT3-ITD benefit from allogeneic HSCT in first complete remission (CR1), (3) it has been shown that this subset of patients are at increased risk of relapse after HSCT. (3,4) Post-transplant relapsed AML is associated with a high mortality rate. The use of chemotherapy followed by donor lymphocyte infusion (DLI) can provide long-term remission in less than 20% of patients.…”

Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile

“… 1 , 2 Retrospective studies show that mutations in FLT3 , NPM1 , and CEBPα are powerful tools to predict outcomes in younger and older patients with NK-AML. 3 - 5 Limited data exists on the role of allogeneic hematopoietic cell transplant (HCT) in NK-AML patients with recurrent genomic abnormalities. 6 - 8 In this retrospective cohort study, we evaluated the outcomes of patients with NK-AML transplanted at a single institution to determine if the widespread implementation of molecular testing in NK-AML patients at the time of diagnosis has impacted the outcomes of patients who ultimately undergo allogeneic HCT.…”